Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vutrisiran in ATTR Amyloidosis With Cardiomyopathy
NCT06679946Phase 3Enrolling by invitation
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- Mar 2028
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of vutrisiran in transthyretin amyloidosis (ATTR), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Frequency of Adverse Events up to 36 Months. Started Dec 2024; status: enrolling by invitation.
02
Drugs
vutrisiran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT06679946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06679946.